|
1
|
Mohamed A, Chen Y, Wu H, Liao J, Cheng B
and Lu Q: Therapeutic advances in the treatment of SLE. Int
Immunopharmacol. 72:218–223. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Parodis I, Tamirou F and Houssiau FA:
Prediction of prognosis and renal outcome in lupus nephritis. Lupus
Sci Med. 7(e000389)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chen Y, Sun J, Zou K, Yang Y and Liu G:
Treatment for lupus nephritis: An overview of systematic reviews
and meta-analyses. Rheumatol Int. 37:1089–1099. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Parikh SV, Almaani S, Brodsky S and Rovin
BH: Update on lupus nephritis: Core curriculum 2020. Am J Kidney
Dis. 76:265–281. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Anders HJ, Saxena R, Zhao MH, Parodis I,
Salmon JE and Mohan C: Lupus nephritis. Nat Rev Dis Primers.
6(7)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shiraz AK, Panther EJ and Reilly CM:
Altered germinal-center metabolism in B cells in autoimmunity.
Metabolites. 12(40)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rovin BH, Furie R, Teng YKO, Contreras G,
Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, et al: A
secondary analysis of the Belimumab international study in lupus
nephritis trial examined effects of belimumab on kidney outcomes
and preservation of kidney function in patients with lupus
nephritis. Kidney Int. 101:403–413. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Onuora S: Adding belimumab improves lupus
nephritis. Nat Rev Rheumatol. 16(601)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Samy E, Wax S, Huard B, Hess H and
Schneider P: Targeting BAFF and APRIL in systemic lupus
erythematosus and other antibody-associated diseases. Int Rev
Immunol. 36:3–19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shi F, Xue R, Zhou X, Shen P, Wang S and
Yang Y: Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune
disease. Immunopharmacol Immunotoxicol. 43:666–673. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dhillon S: Telitacicept: First approval.
Drugs. 81:1671–1675. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fan Y, Gao D and Zhang Z: Telitacicept, a
novel humanized, recombinant TACI-Fc fusion protein, for the
treatment of systemic lupus erythematosus. Drugs Today (Barc).
58:23–32. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H,
Zhao F, Yu H, Qiu L, Li X, et al: Safety and efficacy of
telitacicept in refractory childhood-onset systemic lupus
erythematosus: A self-controlled before-after trial. Lupus.
31:998–1006. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen R, Fu R, Lin Z, Huang C and Huang W:
The efficacy and safety of telitacicept for the treatment of
systemic lupus erythematosus: A real life observational study.
Lupus. 32:94–100. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Aringer M and Petri M: New classification
criteria for systemic lupus erythematosus. Curr Opin Rheumatol.
32:590–596. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gladman DD, Ibañez D and Urowitz MB:
Systemic lupus erythematosus disease activity index 2000. J
Rheumatol. 29:288–291. 2022.PubMed/NCBI
|
|
17
|
Computing VARFFS. R: A language and
environment for statistical computing. 2020.
|
|
18
|
Kaul A, Gordon C, Crow MK, Touma Z,
Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G and Hughes G: .
Systemic lupus erythematosus. Nat Rev Dis Primers.
2(16039)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Golder V and Hoi A: Systemic lupus
erythematosus: An update. Med J Aust. 206:215–220. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Houssiau FA and Ginzler EM: Current
treatment of lupus nephritis. Lupus. 17:426–430. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yusuf IH, Sharma S, Luqmani R and Downes
SM: Hydroxychloroquine retinopathy. Eye (Lond). 31:828–845.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Surówka A, Prowans P, Żołnierczuk M,
Miśkiewicz M, Wawrowski T, Skodda M, Markowska M and
Kędzierska-Kapuza K: The effect of calcineurin inhibitors on MMPs
activity in heart and their side effects-a review of literature.
Int J Mol Sci. 24(10291)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Garrity ST, Jung JY, Zambrowski O, Pichi
F, Su D, Arya M, Waheed NK, Duker JS, Chetrit Y, Miserocchi E, et
al: Early hydroxychloroquine retinopathy: Optical coherence
tomography abnormalities preceding Humphrey visual field defects.
Br J Ophthalmol. 103:1600–1604. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kaye KS, Belley A, Barth P, Lahlou O,
Knechtle P, Motta P and Velicitat P: Effect of
cefepime/enmetazobactam vs. piperacillin/tazobactam on clinical
cure and microbiological eradication in patients with complicated
urinary tract infection or acute pyelonephritis: A randomized
clinical trial. JAMA. 328:1304–1314. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tunnicliffe DJ, Palmer SC, Henderson L,
Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA,
Webster AC and Strippoli GF: Immunosuppressive treatment for
proliferative lupus nephritis. Cochrane Database Syst Rev.
6(CD002922)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kado R and McCune WJ: Ovarian protection
with gonadotropin-releasing hormone agonists during
cyclophosphamide therapy in systemic lupus erythematosus. Best
Pract Res Clin Obstet Gynaecol. 64:97–106. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Galiwango PJ, Delgado DH, Yan R, Kozuszko
S, Smith R, Rao V and Ross HJ: Mycophenolate mofetil dose reduction
for gastrointestinal intolerance is associated with increased rates
of rejection in heart transplant patients. J Heart Lung Transplant.
27:72–77. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ugarte A, Danza A and Ruiz-Irastorza G:
Glucocorticoids and antimalarials in systemic lupus erythematosus:
An update and future directions. Curr Opin Rheumatol. 30:482–489.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang L, Li J, Xu D, Fang J, Van
Vollenhoven R and Zhang F: OP0137 Efficacy And Safety Of
Telitacicept, A Novel Blys/April Dual Inhibitor, In Patients With
Systemic Lupus Erythematosus: A phase 3, randomized,
placebo-controlled 52-week study. Ann Rheumatic Dis. 82:90–91.
2023.
|
|
30
|
Avasare R, Drexler Y, Caster DJ,
Mitrofanova A and Jefferson JA: Management of lupus nephritis: New
treatments and updated guidelines. Kidney360. 4:1503–1511.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lv J, Liu L, Hao C, Li G, Fu P, Xing G,
Zheng H, Chen N, Wang C, Luo P, et al: Randomized phase 2 trial of
telitacicept in patients with IgA nephropathy with persistent
proteinuria. Kidney Int Rep. 8:499–506. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wu D, Li J, Xu D, Merrill JT, van
Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C, et al:
Telitacicept in patients with active systemic lupus erythematosus:
Results of a phase 2b, randomised, double-blind, placebo-controlled
trial. Ann Rheum Dis. 83:475–487. 2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ji L, Geng Y, Zhang X, Deng X, Song Z, Tan
M, Tan Y, Qu C and Zhang Z: B cell pathway dual inhibition for
systemic lupus erythematosus: A prospective single-arm cohort study
of telitacicept. MedComm. 5(e515)2024.PubMed/NCBI View
Article : Google Scholar
|
